PLZ-4
PLZ-4 is a cyclic peptide that selectively binds to bladder cancer cells and primary human bladder cancer cells. PLZ4 conjugated with fluorescent dyes or nanomaterials enables fluorescence imaging and targeted drug delivery to bladder cancer cells. PLZ-4 is used in bladder cancer-related research.
For research use only. We do not sell to patients.
- Formula: C39H59N13O13S3
- Molecular Weight:1014.16
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
PLZ-4 selectively binds to human bladder cancer cell lines 5637, T24, and TCCSUP, but does not bind to normal urothelial cells or other contaminating cells; it retains its binding ability to 5637 bladder cancer cells under urine conditions at pH 6.0[1].
PLZ‑4 relies on its DGR motif and C‑terminal GF residues for binding to 5637 bladder cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 1014.16
-
Formula C39H59N13O13S3
-
Sequence
DCys-Gln-Asp-Gly-Arg-Met-Gly-Phe-DCys (disulfide bridge:DCys1-DCys9)
-
Sequence Shortening
DCys-QDGRMGF-DCys (disulfide bridge:DCys1-DCys9)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Bioluminescent/Fluorescent Imaging Xenograft
Bioluminescent and fluorescent imaging xenograft models use tumor cells engineered to express optical reporters so tumor engraftment, growth, dissemination, and treatment response can be monitored longitudinally in living animals and validated ex vivo. Bioluminescence imaging usually measures luciferase activity after substrate administration and is commonly used as a surrogate for viable reporter-expressing tumor burden, while fluorescence imaging measures reporter or probe emission and can support tumor localization, ex vivo confirmation, or complementary multimodal analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PLZ-4 Related Classifications
HY-P12365 Related Classifications
Powered by Bioz
Keywords